Preprint Review Version 1 This version is not peer-reviewed

The Therapeutic Target of SGLT2 Inhibitors and GLP-1 Agonists Is Superoxide Induced Diuretic Resistance

Version 1 : Received: 17 September 2024 / Approved: 18 September 2024 / Online: 18 September 2024 (11:37:54 CEST)

How to cite: Kaesemeyer MD, W. The Therapeutic Target of SGLT2 Inhibitors and GLP-1 Agonists Is Superoxide Induced Diuretic Resistance. Preprints 2024, 2024091354. https://doi.org/10.20944/preprints202409.1354.v1 Kaesemeyer MD, W. The Therapeutic Target of SGLT2 Inhibitors and GLP-1 Agonists Is Superoxide Induced Diuretic Resistance. Preprints 2024, 2024091354. https://doi.org/10.20944/preprints202409.1354.v1

Abstract

Diuretic resistance is a servomechanism involving superoxide that results from the use of escalating doses of diuretics in the treatment of heart failure. Without intervention this may lead to increased heart failure mortality. Recent heart failure studies involving the use of SGLT2 inhibitors and GLP-1 agonists have shown reductions in the need for loop diuretics along with reductions in hospitalizations for heart failure and cardiovascular mortality. Multiple mechanisms have been proposed to explain the benefits of both these drug classes but this paper is the first to explain and propose superoxide induced diuretic resistance as a therapeutic target for the treatment of heart failure.

Keywords

superoxide; SGLT2 inhibitors; GLP-1 agonists; cardiorenal syndrome; diuretic resistance; heart failure

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.